Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials
Open Access
- 16 June 2026
- journal article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (9) , 8072-8083
Abstract
Aims: Tirzepatide is a once‐weekly glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity across Phase 3 clinical trials. Materials and Methods: This post hoc analysis evaluated results from the SURMOUNT‐1 through ‐5 (including SURMOUNT‐1 3‐year study), SURMOUNT‐OSA and SUMMIT trials. Efficacy and safety of tirzepatide were compared between participants aged ≥ 65 years and < 65 years. Efficacy outcomes, analysed by study, were assessed at varying points depending on trial design. Safety outcomes in the pooled population were assessed throughout the treatment period. Results: Tirzepatide treatment was associated with clinically meaningful weight reduction and favourable treatment differences in cardiometabolic risk factors and quality‐of‐life measures in adults ≥ 65 years, with broadly comparable results to those observed in adults < 65 years. No clinically meaningful differences in adverse event (AE) rates between tirzepatide and placebo were observed in older adults for gastrointestinal tolerability, falls, fractures, depression outcomes, pancreatitis, and renal, hepatic, gallbladder and biliary‐related AEs. No clinically relevant risks beyond those inherent to older age were detected in adults ≥ 65 versus < 65 years. Conclusions: In this post hoc analysis from Phase 3 clinical trials, efficacy and safety profiles of tirzepatide in adults aged ≥ 65 years with obesity were comparable to those in adults aged < 65 years. This study supports tirzepatide's use in older adults when considering risks and benefits.Keywords
Funding Information
- Eli Lilly and Company
This publication has 44 references indexed in Scilit:
- Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐AnalysisObesity, 2026
- Antiobesity Medications for Older Adults—the New, the Good, the Bad, and the UnknownObesity, 2025
- Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trialObesity, 2025
- The impact of lifestyle‐based weight loss in older adults with obesity on muscle and bone health: a balancing actObesity, 2025
- Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical TrialsDiabetes Therapy, 2025
- Unraveling the roles of ectopic adipose depots and physical activity in age‐related mitochondrial declineObesity, 2024
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With ObesityJAMA, 2024
- Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studiesOsteoporosis International, 2019
- Management of Depression in Older AdultsJAMA, 2017
- The SF-36: A simple, effective measure of mobility-disability for epidemiological studiesThe Journal of nutrition, health and aging, 2009